Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Zimberelimab
Synonyms
Therapy Description

Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Zimberelimab GLS-010|AB122|AB-122|GLS010 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03846310 Phase I Carboplatin + Etrumadenant + Pemetrexed Disodium Zimberelimab Carboplatin + Etrumadenant + Pembrolizumab + Pemetrexed Disodium A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Completed USA 3
NCT04087018 Phase I Zimberelimab Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors Completed USA 0
NCT04736173 Phase III Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) Active, not recruiting USA | TUR | GRC 9
NCT04262856 Phase II AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Active, not recruiting USA | CAN | AUS 4
NCT06431633 Phase II Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) Not yet recruiting ESP 0
NCT04656535 Phase I Zimberelimab AB154 AB154 + Zimberelimab AB154 Combined With AB122 for Recurrent Glioblastoma Recruiting USA 0
NCT06048484 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegfilgrastim AB680 + Etrumadenant + Zimberelimab AB680 + Zimberelimab Zimberelimab Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc) Recruiting USA 0
NCT06238921 Phase Ib/II Sacituzumab govitecan-hziy + Zimberelimab Zimberelimab Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Recruiting USA 0


Additional content available in CKB BOOST